TSHA
Taysha Gene Therapies, Inc.
$5.49
-0.05
(-0.90%)
Mkt Cap
1.37B
Volume
1,601,982
52W Range
2.25-7.3
Sector
Healthcare
Beta
1.23
EPS (TTM)
-0.38
P/E Ratio
-16.13
Revenue (TTM)
7.47M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 9.77M | 8.33M | 15.45M | 2.50M | 0 | 0 | 0 |
| Net Income | (109.00M) | (89.30M) | (111.57M) | (166.01M) | (174.52M) | (43.00M) | (1.11M) |
| EPS | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 | -0.03 |
| Free Cash Flow | (93.83M) | (81.60M) | (80.39M) | (113.26M) | (138.60M) | (39.81M) | 135,000 |
| FCF / Share | -0.29 | -0.33 | -0.69 | -2.58 | -3.68 | -2.25 | 0.00 |
| Operating CF | (93.09M) | (81.22M) | (73.02M) | (88.39M) | (117.04M) | (30.73M) | 135,000 |
| Total Assets | 343.32M | 160.36M | 172.73M | 126.28M | 213.96M | 258.88M | 15,000 |
| Total Debt | 18.17M | 63.18M | 61.11M | 59.93M | 63.09M | 0 | 0 |
| Cash & Equiv | 319.77M | 139.04M | 143.94M | 87.88M | 149.10M | 251.25M | 0 |
| Book Value | 246.94M | 71.53M | 74.94M | 949,000 | 95.38M | 251.30M | (135,000) |
| Return on Equity | -0.44 | -1.25 | -1.49 | -174.94 | -1.83 | -0.17 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 5.49M | 0 | 1.99M | 2.30M | 2.02M | 1.79M | 1.11M | 3.41M | 3.60M | 4.75M | 2.40M |
| Net Income | (42.41M) | (27.85M) | (32.73M) | (26.88M) | (21.53M) | (18.79M) | (25.52M) | (20.93M) | (24.06M) | 47.74M | (117.09M) | (24.60M) |
| EPS | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 | -0.09 | -0.10 | -0.09 | -0.10 | 0.26 | -0.93 | -0.38 |
| Free Cash Flow | (40.90M) | (26.97M) | (24.27M) | (20.18M) | (22.40M) | (18.31M) | (21.65M) | (21.70M) | (19.94M) | (16.13M) | (21.45M) | (18.72M) |
| FCF / Share | -0.11 | -0.08 | -0.07 | -0.07 | -0.08 | -0.09 | -0.08 | -0.09 | -0.09 | -0.09 | -0.17 | -0.29 |
| Operating CF | (40.88M) | (26.72M) | (24.17M) | (20.18M) | (22.02M) | (18.31M) | (21.61M) | (21.50M) | (19.80M) | (16.12M) | (17.95M) | (18.77M) |
| Total Assets | 300.35M | 343.32M | 316.55M | 333.33M | 138.36M | 160.36M | 180.22M | 200.39M | 153.00M | 172.73M | 195.77M | 81.54M |
| Total Debt | 17.77M | 18.17M | 69.08M | 59.60M | 61.35M | 63.18M | 62.54M | 57.72M | 60.71M | 61.11M | 59.19M | 59.52M |
| Cash & Equiv | 276.58M | 319.77M | 297.34M | 312.76M | 116.59M | 139.04M | 157.69M | 172.74M | 123.98M | 143.94M | 164.28M | 45.08M |
| Book Value | 211.94M | 246.94M | 218.99M | 248.73M | 55.06M | 71.53M | 88.80M | 108.87M | 53.85M | 74.94M | (49.11M) | (37.11M) |
| Return on Equity | -0.20 | -0.11 | -0.15 | -0.11 | -0.39 | -0.26 | -0.29 | -0.19 | -0.45 | 0.64 | N/A | N/A |
TSHA News
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 6.9% After Analyst Upgrade
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Q4 Earnings Call Highlights
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Better-Than-Expected Earnings